CompletedNCT04506905
Official study titleA 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titration Regimens in Young Adult Participants With Schizophrenia and to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8189 in Elderly Participants With Schizophrenia and Healthy Elderly
This study has finished and is no longer accepting participants.
Multiple locations, including RogersSchizophreniaMedication studyAges 18–80
- Countries
- United States
- Sponsor
- Merck Sharp & Dohme LLC
CompletedNCT01182727
Official study titleSalsalate for the Treatment of Insulin Resistance in People With Schizophrenia
This study has finished and is no longer accepting participants.
In BaltimoreSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
CompletedNCT02118571
Official study titleSchizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application
This study has finished and is no longer accepting participants.
Multiple locations, including BaltimoreSchizophreniaObservational studyAges 18–55
- Countries
- United States
- Sponsor
- Carelon Research
CompletedNCT05339347
Official study titleA Sham-controlled Crossover Study Using Photoneuromodulation to Treatment the Negative Symptoms of Schizophrenia.
This study has finished and is no longer accepting participants.
In São PauloSchizophreniaDevice studyAges 18–55
- Countries
- Brazil
- Sponsor
- University of Sao Paulo
CompletedNCT00644969
Official study titleA Phase 3B 12-Week, Double -Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Varenicline Tartrate (CP-526,555) 1 mg BID for Smoking Cessation in Subjects With Schizophrenia and Schizoaffective Disorder.
This study has finished and is no longer accepting participants.
Multiple locations, including AuroraSchizophreniaMedication studyAges 18–75
- Countries
- United States, Canada
- Sponsor
- Pfizer
CompletedNCT04681807
This study has finished and is no longer accepting participants.
In OttawaSchizophreniaBehavioural studyAges 15–35
- Countries
- Canada
- Sponsor
- The Royal Ottawa Mental Health Centre
CompletedNCT02660775
Official study titleSocial Cognitive Assessment in Psychiatry - Validation of a New Battery: ClaCoS
This study has finished and is no longer accepting participants.
In BronSchizophreniaBehavioural studyAges 18–45
- Countries
- France
- Sponsor
- Hôpital le Vinatier
CompletedNCT05273164
This study has finished and is no longer accepting participants.
In MinneapolisSchizophreniaObservational studyAges 15–45
- Countries
- United States
- Sponsor
- University of Minnesota
CompletedNCT05664594
This study has finished and is no longer accepting participants.
In MinneapolisSchizophreniaDevice studyAges 15–45
- Countries
- United States
- Sponsor
- University of Minnesota
CompletedNCT02744989
Official study titleSTIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia (SCH)
This study has finished and is no longer accepting participants.
Multiple locations, including BronSchizophreniaDevice studyAges 18–65
- Countries
- France, Monaco
- Sponsor
- Hospices Civils de Lyon
CompletedNCT00001258
Official study titleStudies of Frontal Lobe Function During Cognitive Stimulation as Measured With Oxygen-15 Water Positron Emission Tomography in Normal Subjects and Patients With Neuropsychiatric Disorders
This study has finished and is no longer accepting participants.
In BethesdaSchizophreniaObservational studyAges 18–90
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH) (Government agency)
CompletedNCT04325737
What is this study about?Researchers compared SEP-363856 and placebo, tracking side effects to assess safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Omuta-shiSchizophreniaMedication studyAges 18–65
- Countries
- Japan
- Sponsor
- Sumitomo Pharma Co., Ltd.
